Insys' Subsys becomes Bass' latest target

Kyle Bass' Coalition for Affordable Drugs XI filed three new inter partes review (IPR) petitions with the Patent Trials and Appeals Board (PTAB) of the U.S. Patent and Trademark Office challenging three patents from Insys Therapeutics Inc. (NASDAQ:INSY) that cover Subsys fentanyl sublingual spray.

The petition challenges U.S. Patents Nos. 8,835,459; 8,486,972; and 8,835,460. The '459 and '972 patents claim formulations of Subsys and expire in 2027 and 2030, respectively. The '460 patent claims a formulation and administration device for Subsys and a method of treating pain using the drug; the patent expires in 2027. ...